Primidone Market

The Primidone market is projected to grow at a CAGR of 3.7% from 2025 to 2035, driven by the persistent global burden of seizure disorders, increasing awareness of essential tremor management, and the need for cost-effective antiepileptic drugs (AEDs). Primidone is a barbiturate-class anticonvulsant that acts by enhancing GABAergic neurotransmission and modulating voltage-gated sodium channels, thereby stabilizing neuronal membranes and reducing excitability. It is metabolized into phenobarbital and phenylethylmalonamide (PEMA), both of which contribute to its antiepileptic effect.

Primidone is primarily used in the treatment of generalized tonic-clonic seizures and complex partial seizures, as well as essential tremor when first-line therapies are ineffective or contraindicated. Its long-established clinical utility, particularly in combination with other AEDs, ensures ongoing demand, especially in regions where newer alternatives remain less accessible due to cost or availability constraints. Though newer anticonvulsants with improved side effect profiles have entered the market, Primidone remains in use for specific patient populations and is frequently prescribed where decades of clinical experience support its efficacy.

North America leads the Primidone market due to a large population affected by epilepsy and essential tremor, mature healthcare systems, and established prescribing patterns. Europe follows with stable demand supported by national health systems that maintain older yet effective therapies. The Asia-Pacific region is projected to grow steadily as epilepsy awareness increases, generic drug access expands, and cost-sensitive markets favor established treatments. Latin America and the Middle East & Africa exhibit gradual growth, supported by WHO-backed epilepsy care initiatives and increasing access to neurology care.